ClinicalTrials.gg
Active, not recruitingNCT03863132REBOOT-PARADOXUpdated Nov 9, 2026

accuRate Evaluation of Benefit With Optimal Medical Treatment With or Without Transcatheter Valve Repair of PARADOXical Low Flow Low Gradient Aortic Stenosis

An interventional study of TAVR in Aortic Valve Stenosis, sponsored by IHF GmbH - Institut für Herzinfarktforschung. Active, not recruiting at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by IHF GmbH - Institut für Herzinfarktforschung · Not applicable, Interventional, and Treatment

How we know

Updated Nov 9, 2026Results publication addedFirst sites in Italy and Switzerland+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Aortic Valve Stenosis with a site in Germany — 39 open to participants now, 58 under way, 3 of them phase 3. Aortic Valve Stenosis · Germany.

Enrollment
61st of 93
120 · median 220
Started
2019
with 11 others
No phase
82 of 191
13 open now
Primary completion
2027-09
later than 36 of 57 live
Registered
110th of 191
by date

Among the 191 studies in Aortic Valve Stenosis with a site in Germany, this one is the 61st largest by enrollment of the 93 interventional ones that give a count, is one of 12 that started in 2019, is one of 82 with no phase, reaches primary completion later than 36 of the 57 other live ones, and was the 110th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

39 of the 191 studies in Aortic Valve Stenosis with a site in Germany are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Aortic Valve Stenosis with a site in Germany, or all of them as a file.
02

Study summary

Aim of this study is to evaluate whether microsurgical repair or replacement of the aortic valve is a treatment option for a subgroup of patients suffering from aortic Stenosis.

Read the detailed description

Stenosis of the aortic valve leads to a narrowing of the valve, consequently to low blood flow from the heart into the Aorta, and is associated with symptoms like fatigue, breathlessness, dizziness, fainting, and chest pain. For many of the patients suffering from severe aortic stenosis surgical or catheter-assisted repair or replacement of the damaged aortic valve has been proven to be a safe and effective treatment option.

Probably about 20-30% of patients suffering from severe aortic stenosis display a deviation from the usually observed disease pattern: These patients do not show the typical high pressure difference between the left ventricle (heart chamber) and the aorta (transvalvular gradient; "paradoxical" low flow/low gradient aortic stenosis). For these patients it is not yet clear, if microsurgical repair of the aortic valve (transcatheter aortic valve repair - TAVR) should be a treatment option as well.

REBOOT-PARADOX evaluates whether TAVR is advantageous compared to optimal medical Treatment alone for patients suffering from paradoxical aortic stenosis. Two thirds of the participating patients will be treated by TAVR, one third will receive medical Treatment alone.

03

Conditions studied

  • Aortic Valve Stenosis

Keywords

  • Aortic stenosis
  • Low flow
  • Low gradient
  • Transcatheter aortic valve replacement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • I1. Patients with symptomatic native aortic valve stenosis and age ≥18 years
  • I2. Aortic valve area (AVA) ≤ 1 cm2 or indexed AVA ≤ 0.6 cm2/m2, mean aortic gradient \< 40 mmHg and stroke volume index (SVI) \< 35ml/m2
  • I3. ≥ 50%
  • I4. MDCT aortic valve calcium score men > 2000AU, women > 1200AU OR the likelihood criteria are fulfilled (symptoms without other explanation and LV hypertrophy; age \< 70 yrs., AVS \< 0.8 cm2; SVI \< 35ml/m2 confirmed by 3D TOE, MRI or invasive; reduced LV longitudinal function without other reason)
  • I5. Heart team agrees on eligibility for TAVR
  • I6. Written
  • I7. Negative pregnancy test in women with

Exclusion criteria

Exclusion Criteria:

  • E1. Hemodynamic instability
  • E2. Cardiogenic shock
  • E3. Pre-existing mechanical or bio-prosthetic valve in any position
  • E4. Concomitant severe valvular heart disease
  • E5. Pre-existing or active endocarditis
  • E6. Need for heart surgery due to other conditions
  • E7. Aortic valve is congenital unicuspid or congenital bicuspid
  • E8. Hypertrophic cardiomyopathy with or without obstruction
  • E9. Echocardiographic evidence of intracardiac mass, thrombus or vegetation
  • E10. Acute myocardial infarction within 1 month before intended AS-treatment
  • E11. Renal replacement therapy
  • E12. Estimated \< 24 months (730 days) due to carcinomas end stage liver disease or renal disease
  • E13. Currently participating in an drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
  • E14. Patient refuses aortic valve repair
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    TAVR Group

    Patients will be treated by transcatheter aortic valve repair (TAVR).

    Device: TAVR

  • No intervention
    Medical Treatment Group

    Patients will receive optimal medical treatment alone.

Interventions

  • DeviceTAVR

    Repair of defective aortic valve by microsurgical Intervention.

06

What researchers measure

Primary outcomes

  1. Time to death

    All-cause mortality

    Time frame: 24 months after last-patient-in

Secondary outcomes

  1. Cardiovascular mortality

    Death because of cardiovascular events

    Time frame: 5 years after index treatment

  2. Re-hospitalization due to heart failure

    Number of hospital stays after randomization

    Time frame: 5 years after index treatment

  3. Incidence of neurological events - incidence of strokes

    Number of strokes

    Time frame: 5 years after randomization

  4. Incidence of neurological Events - incidence of transient ischaemic attacks

    Number of transient ischaemic attacks

    Time frame: 5 years after randomization

  5. Cardiac functionality - left ventricular function

    Echocardiographic measurement of left ventricular ejection fraction in %

    Time frame: 5 years after randomization

  6. Cardiac functionality - aortic valve hemodynamics

    Measurement of aortic pressure in mmHg

    Time frame: 5 years after randomization

  7. Patients' quality of life

    EQ5D-score in %

    Time frame: 5 years after randomization

  8. Device reliability

    Number of reinterventions (TAVR arm only)

    Time frame: 5 years after randomization

07

Study locations

15 sites
08

References and documents

Publications

  • Mehilli J, Steffen J, Rudolph T, Haum M, Giannini C, Stark K, Ince H, Conradi L, Joner M, Schafer A, Karcher AK, Landt M, Adam M, Thiele H, Geisler T, Jochheim D, Hagl C, Zeymer U, Windecker S, Massberg S; REBOOT-PARADOX-Trial Investigators. Transcatheter Aortic Valve Replacement or Medical Treatment for Paradoxical Low-Flow, Low-Gradient Aortic Valve Stenosis: REBOOT-PARADOX. J Am Coll Cardiol. 2026 Aug 28:S0735-1097(26)07496-6. doi: 10.1016/j.jacc.2026.08.017. Online ahead of print. PubMed 42663358 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Sep 2027, 97 months after the start.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 97 months is above that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2028 → Sep 2027, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2019
First posted
Mar 5, 2019
StartActual
Jul 3, 2019
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2027was Mar 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
15 sites added, 1 site removed — first sites in Italy and Switzerland
Show 15 added (12 Germany, 2 Italy, 1 Switzerland)
  • Universitätsklinikum Tübingen · Tübingen, Germany
  • Deutsches Herzzentrum München · München, Germany
  • Klinikum der Universität München-Großhadern · München, Germany
  • Universitäres Herz- u. Gefäßzentrum Hamburg · Hamburg, Germany
  • Kerckhoff-Klinik GmbH · Bad Nauheim, Germany
  • Herz- und Gefäßzentrum Bad Bevensen · Bad Bevensen, Germany
  • Universitätsmedizin Rostock, Klinik und Poliklinik für Kardiologie · Rostock, Germany
  • Herz- und Diabeteszentrum Nordrhein-Westfalen Bad Oeynhausen · Bad Oeynhausen, Germany
  • Herzzentrum der Universität Köln · Cologne, Germany
  • Klinikum der Stadt Ludwigshafen a. Rh. · Ludwigshafen am Rhein, Germany
  • Herzzentrum Leipzig · Leipzig, Germany
  • Segeberger Kliniken, Herzzentrum · Bad Segeberg, Germany
  • Humanitas Mirasole S.P.A · Milan, Italy
  • Azienda Ospedaliero Universitaria Pisana · Pisa, Italy
  • Universitätsspital Zürich, Universitätres Herzzentrum Zürich · Zurich, Switzerland
Show 1 removed
  • Klinikum der Universität München-Großhadern · München, Germany
Nov 9, 2026
Study completion
Mar 1, 2028→Sep 1, 2027
Nov 9, 2026
Publications
Results publication added: Mehilli J, Steffen J, Rudolph T, Haum M, Giannini C, Stark K, Ince H, Conradi L, Joner M, Schafer A, Karcher AK, Landt M, Adam M, Thiele H, Geisler T, Jochheim… PubMed 42663358 ↗
Nov 9, 2026
Sponsor
Collaborators added: Boston Scientific Corporation; collaborators removed: Boston Scientific Group
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Publications Results publication added: Mehilli J, Steffen J, Rudolph T, Haum M, Giannini C, Stark K, Ince H, Conradi L, Joner M, Schafer A, Karcher AK, Landt M, Adam M, Thiele H, Geisler T, Jochheim… PubMed 42663358 ↗
    15 sites added, 1 site removed — first sites in Italy and Switzerland
    Show 15 added (12 Germany, 2 Italy, 1 Switzerland)
    • Universitätsklinikum Tübingen · Tübingen, Germany
    • Deutsches Herzzentrum München · München, Germany
    • Klinikum der Universität München-Großhadern · München, Germany
    • Universitäres Herz- u. Gefäßzentrum Hamburg · Hamburg, Germany
    • Kerckhoff-Klinik GmbH · Bad Nauheim, Germany
    • Herz- und Gefäßzentrum Bad Bevensen · Bad Bevensen, Germany
    • Universitätsmedizin Rostock, Klinik und Poliklinik für Kardiologie · Rostock, Germany
    • Herz- und Diabeteszentrum Nordrhein-Westfalen Bad Oeynhausen · Bad Oeynhausen, Germany
    • Herzzentrum der Universität Köln · Cologne, Germany
    • Klinikum der Stadt Ludwigshafen a. Rh. · Ludwigshafen am Rhein, Germany
    • Herzzentrum Leipzig · Leipzig, Germany
    • Segeberger Kliniken, Herzzentrum · Bad Segeberg, Germany
    • Humanitas Mirasole S.P.A · Milan, Italy
    • Azienda Ospedaliero Universitaria Pisana · Pisa, Italy
    • Universitätsspital Zürich, Universitätres Herzzentrum Zürich · Zurich, Switzerland
    Show 1 removed
    • Klinikum der Universität München-Großhadern · München, Germany
    Study completion Mar 1, 2028→Sep 1, 2027
    Sponsor Collaborators added: Boston Scientific Corporation; collaborators removed: Boston Scientific Group
    + 3 other changes: verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03863132
Lead sponsor
IHF GmbH - Institut für Herzinfarktforschung
Responsible party
Sponsor
First posted
Mar 5, 2019
Start date
Jul 3, 2019
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Steffen Massberg, Prof. Dr.
principal investigator · University Clinic Munich

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion